| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,686 | 2,583 |
| Depreciation expense | 682 | 487 |
| Impairment of fixed assets | 83 | 82 |
| Loss on the sale and disposal of fixed assets | -339 | -11 |
| Non-cash stock compensation expense | 2,527 | 1,364 |
| Non-cash lease expense | 232 | 151 |
| Non-cash interest expense | 103 | 69 |
| Change in fair value of warrant liability | -21,718 | -20,572 |
| Accretion of debt discount | 97 | 76 |
| Prepaid expenses and other current assets | 1,710 | 1,771 |
| Other assets | 22 | -18 |
| Accounts payable | 769 | 1,513 |
| Accrued expenses | -35 | -1,243 |
| Lease liability | -404 | -275 |
| Net cash used in operating activities | -27,743 | -17,507 |
| Purchase of fixed assets | 178 | 34 |
| Proceeds from the sale of fixed assets | 27 | - |
| Net cash used in investing activities | -151 | -34 |
| Proceeds from issuance of common stock in registered direct offering | 14,331 | 15,044 |
| Proceeds from sale of common stock, net of issuance costs | 5,038 | 5,038 |
| Proceeds from option exercises | 512 | 492 |
| Principal payments on term loan | -7,500 | -5,000 |
| Payment of deferred debt issuance costs | 178 | - |
| Net cash provided by financing activities | 12,203 | 15,574 |
| Net decrease in cash, cash equivalents and restricted cash | -15,691 | -1,967 |
| Cash and cash equivalents at beginning of period | 102,920 | - |
| Cash and cash equivalents at end of period | 87,229 | - |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)